EXPERIMENTAL TEST OF IN PRISON DRUG ABUSE TREATMENT

这项为期四年的研究将评估一种创新的 开始实施药物治疗和艾滋病毒/艾滋病预防方案， 马萨诸塞州监狱的承包商，光谱成瘾服务， Inc.该州的惩教部（DOC）和光谱 制定了一项为期六个月的创新住宿计划，并正在实施 在1993年秋季，将以统一的方式在6个 不同的设施。将优先治疗那些 被诊断为复发和/或累犯的高风险。 这项研究将利用现有治疗方法的不足 相对于预期的需求进行控制实验的插槽。一个 估计目前有7,000名囚犯在押，至少三分之二的人 每年有2,400多名新囚犯，有吸毒史， 参与和滥用。该计划的能力将限于 每年治疗约1,100人。分配这些稀缺的治疗 槽，囚犯将被筛选进入治疗和池 的罪犯被确定为合适的，然后将选择治疗 随机分配。这将产生两个种群， 每个受试者：分配给药物治疗计划的“实验者”， 和未如此指定的“控制”。将向受试者提供基线 从监狱释放后不久接受采访，并在四岁时再次接受采访。 释放后的12个月。治疗结局指标 将包括从复发到持续药物滥用的时间， 犯罪时间和艾滋病毒风险恢复时间 行为这些结果事件的指标将包括自我报告的 复发，犯罪和艾滋病毒风险行为，尿检，和官方 刑事司法记录

This four-year study will evaluate treatment outcomes of an innovative drug treatment and HIV/AIDS prevention program begin implemented in the Massachusetts state prisons by a contractor, Spectrum Addiction Services, Inc. The state's Department of Correction (DOC) and Spectrum have developed an innovative six-month residential program, being implemented in the fall of 1993, that will be delivered in a uniform manner in six different facilities. Priority for treatment will be given to those diagnosed as being a high-risk of relapse and/or recidivism. The study will take advantage of the shortfall of available treatment slots relative to expected demand to conduct a controlled experiment. An estimated 7,000 prisoners currently in custody, and at least two-thirds of the 2,400-plus incoming prisoners each year, have histories of drug- involvement and abuse. The capacity of the program will be limited to treating approximately 1,100 per year. To allocate these scarce treatment slots, prisoners will be screened for admission to treatment and the pool of offenders identified as suitable will then be selected for treatment by random assignment. This will yield two populations, having 700 subjects each: "experimentals" assigned to the drug treatment program, and "controls" not so assigned. Subjects will be given baseline interviews shortly after release from prison, and reinterviewed at four months and twelve months following release. Treatment outcome measures will include time to relapse to sustained drug abuse and, separately, time to commission of a crime and time to resumption of HIV risk behavior. Indicators of these outcomes events will include self-reported relapse, criminality, and HIV-risk behaviors, urine tests, and official criminal justice records.